{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T04:51:47Z","timestamp":1762145507739,"version":"3.37.3"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T00:00:00Z","timestamp":1575936000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T00:00:00Z","timestamp":1575936000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100008363","name":"Danish Cancer Society","doi-asserted-by":"crossref","award":["R56-A3307-12-S2"],"award-info":[{"award-number":["R56-A3307-12-S2"]}],"id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Causes Control"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s10552-019-01252-5","type":"journal-article","created":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T06:02:35Z","timestamp":1575957755000},"page":"139-151","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Associations of low-dose aspirin or other NSAID use with prostate cancer risk in the Danish Diet, Cancer and Health Study"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0774-4259","authenticated-orcid":false,"given":"Charlotte","family":"Skriver","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Dehlendorff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Borre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus","family":"Brasso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Signe Benzon","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Tj\u00f8nneland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anton","family":"Potteg\u00e5rd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesper","family":"Hallas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik Toft","family":"S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00f8ren","family":"Friis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,12,10]]},"reference":[{"key":"1252_CR1","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1093\/annonc\/mdu225","volume":"26","author":"J Cuzick","year":"2015","unstructured":"Cuzick J, Thorat MA, Bosetti C, Brown PH, Burn J, Cook NR, Ford LG, Jacobs EJ, Jankowski JA, La Vecchia C, Law M, Meyskens F, Rothwell PM, Senn HJ, Umar A (2015) Estimates of benefits and harms of prophylactic use of aspirin in the general population. Ann Oncol 26:47\u201357. https:\/\/doi.org\/10.1093\/annonc\/mdu225","journal-title":"Ann Oncol"},{"key":"1252_CR2","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1186\/s12885-018-4156-5","volume":"18","author":"Y Qiao","year":"2018","unstructured":"Qiao Y, Yang T, Gan Y, Li W, Wang C, Gong Y, Lu Z (2018) Associations between aspirin use and the risk of cancers: a meta-analysis of observational studies. BMC Cancer 18:288. https:\/\/doi.org\/10.1186\/s12885-018-4156-5","journal-title":"BMC Cancer"},{"key":"1252_CR3","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/1741-7015-12-55","volume":"12","author":"Y Liu","year":"2014","unstructured":"Liu Y, Chen JQ, Xie L, Wang J, Li T, He Y, Gao Y, Qin X, Li S (2014) Effect of aspirin and other non-steroidal anti-inflammatory drugs on prostate cancer incidence and mortality: a systematic review and meta-analysis. BMC Med 12:55. https:\/\/doi.org\/10.1186\/1741-7015-12-55","journal-title":"BMC Med"},{"key":"1252_CR4","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1186\/1477-7819-12-304","volume":"12","author":"X Wang","year":"2014","unstructured":"Wang X, Lin YW, Wu J, Zhu Y, Xu XL, Xu X, Liang Z, Hu ZH, Li SQ, Zheng XY, Xie LP (2014) Meta-analysis of nonsteroidal anti-inflammatory drug intake and prostate cancer risk. World J Surg Oncol 12:304. https:\/\/doi.org\/10.1186\/1477-7819-12-304","journal-title":"World J Surg Oncol"},{"key":"1252_CR5","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1007\/s11255-014-0703-4","volume":"46","author":"TB Huang","year":"2014","unstructured":"Huang TB, Yan Y, Guo ZF, Zhang XL, Liu H, Geng J, Yao XD, Zheng JH (2014) Aspirin use and the risk of prostate cancer: a meta-analysis of 24 epidemiologic studies. Int Urol Nephrol 46:1715\u20131728. https:\/\/doi.org\/10.1007\/s11255-014-0703-4","journal-title":"Int Urol Nephrol"},{"key":"1252_CR6","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3389\/fonc.2018.00437","volume":"8","author":"Z Shang","year":"2018","unstructured":"Shang Z, Wang X, Yan H, Cui B, Wang Q, Wu J, Cui X, Li J, Ou T, Yang K (2018) Intake of non-steroidal anti-inflammatory drugs and the risk of prostate cancer: a meta-analysis. Front Oncol 8:437. https:\/\/doi.org\/10.3389\/fonc.2018.00437","journal-title":"Front Oncol"},{"key":"1252_CR7","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.critrevonc.2018.09.013","volume":"132","author":"CM Sauer","year":"2018","unstructured":"Sauer CM, Myran DT, Costentin CE, Zwisler G, Safder T, Papatheodorou S, Mucci LA (2018) Effect of long term aspirin use on the incidence of prostate cancer: a systematic review and meta-analysis. Crit Rev Oncol Hematol 132:66\u201375. https:\/\/doi.org\/10.1016\/j.critrevonc.2018.09.013","journal-title":"Crit Rev Oncol Hematol"},{"key":"1252_CR8","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/nrc.2016.4","volume":"16","author":"DA Drew","year":"2016","unstructured":"Drew DA, Cao Y, Chan AT (2016) Aspirin and colorectal cancer: the promise of precision chemoprevention. Nat Rev Cancer 16:173\u2013186. https:\/\/doi.org\/10.1038\/nrc.2016.4","journal-title":"Nat Rev Cancer"},{"key":"1252_CR9","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/s0140-6736(18)31133-4","volume":"392","author":"PM Rothwell","year":"2018","unstructured":"Rothwell PM, Cook NR, Gaziano JM, Price JF, Belch JFF, Roncaglioni MC, Morimoto T, Mehta Z (2018) Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. Lancet 392:387\u2013399. https:\/\/doi.org\/10.1016\/s0140-6736(18)31133-4","journal-title":"Lancet"},{"key":"1252_CR10","doi-asserted-by":"publisher","first-page":"4790","DOI":"10.1158\/0008-5472.can-18-0326","volume":"78","author":"X Wang","year":"2018","unstructured":"Wang X, Chan AT, Slattery ML, Chang-Claude J, Potter JD, Gallinger S, Caan B, Lampe JW, Newcomb PA, Zubair N, Hsu L, Schoen RE, Hoffmeister M, Brenner H, Le Marchand L, Peters U, White E (2018) Influence of smoking, body mass index, and other factors on the preventive effect of nonsteroidal anti-inflammatory drugs on colorectal cancer risk. Cancer Res 78:4790\u20134799. https:\/\/doi.org\/10.1158\/0008-5472.can-18-0326","journal-title":"Cancer Res"},{"key":"1252_CR11","doi-asserted-by":"publisher","first-page":"4270","DOI":"10.1200\/jco.2016.67.4283","volume":"34","author":"NM Iyengar","year":"2016","unstructured":"Iyengar NM, Gucalp A, Dannenberg AJ, Hudis CA (2016) Obesity and cancer mechanisms: tumor microenvironment and inflammation. J Clin Oncol 34:4270\u20134276. https:\/\/doi.org\/10.1200\/jco.2016.67.4283","journal-title":"J Clin Oncol"},{"key":"1252_CR12","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1158\/1940-6207.capr-16-0209","volume":"9","author":"J Todoric","year":"2016","unstructured":"Todoric J, Antonucci L, Karin M (2016) Targeting inflammation in cancer prevention and therapy. Cancer Prev Res 9:895\u2013905. https:\/\/doi.org\/10.1158\/1940-6207.capr-16-0209","journal-title":"Cancer Prev Res"},{"key":"1252_CR13","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1002\/ijc.25811","volume":"128","author":"PK Dhillon","year":"2011","unstructured":"Dhillon PK, Kenfield SA, Stampfer MJ, Giovannucci EL (2011) Long-term aspirin use and the risk of total, high-grade, regionally advanced and lethal prostate cancer in a prospective cohort of health professionals, 1988\u20132006. Int J Cancer 128:2444\u20132452. https:\/\/doi.org\/10.1002\/ijc.25811","journal-title":"Int J Cancer"},{"key":"1252_CR14","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1080\/14034940601047986","volume":"35","author":"A Tj\u00f8nneland","year":"2007","unstructured":"Tj\u00f8nneland A, Olsen A, Boll K, Stripp C, Christensen J, Engholm G, Overvad K (2007) Study design, exposure variables, and socioeconomic determinants of participation in Diet, Cancer and Health: a population-based prospective cohort study of 57,053 men and women in Denmark. Scand J Public Health 35:432\u2013441. https:\/\/doi.org\/10.1080\/14034940601047986","journal-title":"Scand J Public Health"},{"key":"1252_CR15","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1177\/1403494810393562","volume":"39","author":"ML Gjerstorff","year":"2011","unstructured":"Gjerstorff ML (2011) The Danish Cancer Registry. Scand J Public Health 39:42\u201345. https:\/\/doi.org\/10.1177\/1403494810393562","journal-title":"Scand J Public Health"},{"key":"1252_CR16","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1093\/ije\/dyw213","volume":"46","author":"A Potteg\u00e5rd","year":"2017","unstructured":"Potteg\u00e5rd A, Schmidt SA, Wallach-Kildemoes H, S\u00f8rensen HT, Hallas J, Schmidt M (2017) Data resource profile: the Danish National Prescription Registry. Int J Epidemiol 46:798\u2013798f. https:\/\/doi.org\/10.1093\/ije\/dyw213","journal-title":"Int J Epidemiol"},{"key":"1252_CR17","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2147\/clep.s91125","volume":"7","author":"M Schmidt","year":"2015","unstructured":"Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L, S\u00f8rensen HT (2015) The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol 7:449\u2013490. https:\/\/doi.org\/10.2147\/clep.s91125","journal-title":"Clin Epidemiol"},{"key":"1252_CR18","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1177\/1403494811405098","volume":"39","author":"M Baadsgaard","year":"2011","unstructured":"Baadsgaard M, Quitzau J (2011) Danish registers on personal income and transfer payments. Scand J Public Health 39:103\u2013105. https:\/\/doi.org\/10.1177\/1403494811405098","journal-title":"Scand J Public Health"},{"key":"1252_CR19","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s10654-014-9930-3","volume":"29","author":"M Schmidt","year":"2014","unstructured":"Schmidt M, Pedersen L, S\u00f8rensen HT (2014) The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol 29:541\u2013549. https:\/\/doi.org\/10.1007\/s10654-014-9930-3","journal-title":"Eur J Epidemiol"},{"key":"1252_CR20","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.3109\/0284186x.2013.831474","volume":"52","author":"RV Karlsen","year":"2013","unstructured":"Karlsen RV, Larsen SB, Christensen J, Brasso K, Friis S, Tj\u00f8nneland A, Dalton SO (2013) PSA testing without clinical indication for prostate cancer in relation to socio-demographic and clinical characteristics in the Danish Diet, Cancer and Health Study. Acta Oncol 52:1609\u20131614. https:\/\/doi.org\/10.3109\/0284186x.2013.831474","journal-title":"Acta Oncol"},{"key":"1252_CR21","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology (2018) Guidelines for ATC classification and DDD assignment 2019. Oslo, Norway. https:\/\/www.whocc.no\/filearchive\/publications\/2019_guidelines_web.pdf. Accessed 23 May 2019"},{"key":"1252_CR22","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a030361","author":"CH Pernar","year":"2018","unstructured":"Pernar CH, Ebot EM, Wilson KM, Mucci LA (2018) The epidemiology of prostate cancer. Cold Spring Harb Perspect Med. https:\/\/doi.org\/10.1101\/cshperspect.a030361","journal-title":"Cold Spring Harb Perspect Med"},{"key":"1252_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2018.04.001","author":"R Campi","year":"2018","unstructured":"Campi R, Brookman-May SD, Subiela Henr\u00edquez JD, Akdo\u011fan B, Brausi M, Klatte T, Langenhuijsen JF, Linares-Espinos E, Marszalek M, Roupret M, Stief CG, Volpe A, Minervini A, Rodriguez-Faba O (2018) Impact of metabolic diseases, drugs, and dietary factors on prostate cancer risk, recurrence, and survival: a systematic review by the European Association of Urology Section of Oncological Urology. Eur Urol Focus. https:\/\/doi.org\/10.1016\/j.euf.2018.04.001","journal-title":"Eur Urol Focus"},{"key":"1252_CR24","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1111\/bcpt.12946","volume":"122","author":"A Potteg\u00e5rd","year":"2018","unstructured":"Potteg\u00e5rd A, Friis S, St\u00fcrmer T, Hallas J, Bahmanyar S (2018) Considerations for pharmacoepidemiological studies of drug\u2013cancer associations. Basic Clin Pharmacol Toxicol 122:451\u2013459. https:\/\/doi.org\/10.1111\/bcpt.12946","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"1252_CR25","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/pds.4145","volume":"26","author":"A Potteg\u00e5rd","year":"2016","unstructured":"Potteg\u00e5rd A, Hallas J (2016) New use of prescription drugs prior to a cancer diagnosis. Pharmacoepidemiol Drug Saf 26:223\u2013227. https:\/\/doi.org\/10.1002\/pds.4145","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1252_CR26","doi-asserted-by":"publisher","first-page":"496","DOI":"10.2307\/2670170","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496\u2013509. https:\/\/doi.org\/10.2307\/2670170","journal-title":"J Am Stat Assoc"},{"key":"1252_CR27","doi-asserted-by":"publisher","first-page":"5709","DOI":"10.1002\/sim.3402","volume":"27","author":"PK Ruan","year":"2008","unstructured":"Ruan PK, Gray RJ (2008) Analyses of cumulative incidence functions via non-parametric multiple imputation. Stat Med 27:5709\u20135724. https:\/\/doi.org\/10.1002\/sim.3402","journal-title":"Stat Med"},{"key":"1252_CR28","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1093\/biostatistics\/kxq018","volume":"11","author":"A Allignol","year":"2010","unstructured":"Allignol A, Beyersmann J (2010) Software for fitting nonstandard proportional subdistribution hazards models. Biostatistics 11:674\u2013675. https:\/\/doi.org\/10.1093\/biostatistics\/kxq018","journal-title":"Biostatistics"},{"key":"1252_CR29","unstructured":"R Core Team (2013) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. https:\/\/www.R-project.org\/. Accessed 23 May 2019"},{"key":"1252_CR30","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.1158\/1055-9965.EPI-10-0942","volume":"19","author":"TM Brasky","year":"2010","unstructured":"Brasky TM, Velicer CM, Kristal AR, Peters U, Potter JD, White E (2010) Nonsteroidal anti-inflammatory drugs and prostate cancer risk in the VITamins And Lifestyle (VITAL) cohort. Cancer Epidemiol Biomark Prev 19:3185\u20133188. https:\/\/doi.org\/10.1158\/1055-9965.EPI-10-0942","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"1252_CR31","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1136\/jim-2016-000275","volume":"65","author":"U Iqbal","year":"2017","unstructured":"Iqbal U, Yang HC, Jian WS, Yen Y, Li YJ (2017) Does aspirin use reduce the risk for cancer? J Investig Med 65:391\u2013392. https:\/\/doi.org\/10.1136\/jim-2016-000275","journal-title":"J Investig Med"},{"key":"1252_CR32","doi-asserted-by":"publisher","first-page":"e16412","DOI":"10.1371\/journal.pone.0016412","volume":"6","author":"SM Mahmud","year":"2011","unstructured":"Mahmud SM, Franco EL, Turner D, Platt RW, Beck P, Skarsgard D, Tonita J, Sharpe C, Aprikian AG (2011) Use of non-steroidal anti-inflammatory drugs and prostate cancer risk: a population-based nested case-control study. PLoS ONE 6:e16412. https:\/\/doi.org\/10.1371\/journal.pone.0016412","journal-title":"PLoS ONE"},{"key":"1252_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32083","author":"KK Tsoi","year":"2018","unstructured":"Tsoi KK, Ho JM, Chan FC, Sung JJ (2018) Long-term use of low-dose aspirin for cancer prevention: a 10-year population cohort study in Hong Kong. Int J Cancer. https:\/\/doi.org\/10.1002\/ijc.32083","journal-title":"Int J Cancer"},{"key":"1252_CR34","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1158\/1055-9965.epi-18-0965","volume":"28","author":"LM Hurwitz","year":"2018","unstructured":"Hurwitz LM, Joshu CE, Barber JR, Prizment AE, Vitolins MZ, Jones MR, Folsom AR, Han M, Platz EA (2018) Aspirin and non-aspirin NSAID use and prostate cancer incidence, mortality, and case-fatality in the atherosclerosis risk in communities study. Cancer Epidemiol Biomark Prev 28:563\u2013569. https:\/\/doi.org\/10.1158\/1055-9965.epi-18-0965","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"1252_CR35","doi-asserted-by":"publisher","first-page":"984","DOI":"10.4143\/crt.2017.248","volume":"50","author":"M Kang","year":"2018","unstructured":"Kang M, Ku JH, Kwak C, Kim HH, Jeong CW (2018) Effects of aspirin, nonsteroidal anti-inflammatory drugs, statin, and COX2 inhibitor on the developments of urological malignancies: a population-based study with 10-year follow-up data in Korea. Cancer Res Treat 50:984\u2013991. https:\/\/doi.org\/10.4143\/crt.2017.248","journal-title":"Cancer Res Treat"},{"key":"1252_CR36","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1007\/s10552-016-0785-7","volume":"27","author":"C Skriver","year":"2016","unstructured":"Skriver C, Dehlendorff C, Borre M, Brasso K, S\u00f8rensen HT, Hallas J, Larsen SB, Tj\u00f8nneland A, Friis S (2016) Low-dose aspirin or other nonsteroidal anti-inflammatory drug use and prostate cancer risk: a nationwide study. Cancer Causes Control 27:1067\u20131079. https:\/\/doi.org\/10.1007\/s10552-016-0785-7","journal-title":"Cancer Causes Control"},{"key":"1252_CR37","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.ejca.2015.02.003","volume":"51","author":"T Nordstr\u00f6m","year":"2015","unstructured":"Nordstr\u00f6m T, Clements M, Karlsson R, Adolfsson J, Gr\u00f6nberg H (2015) The risk of prostate cancer for men on aspirin, statin or antidiabetic medications. Eur J Cancer 51:725\u2013733. https:\/\/doi.org\/10.1016\/j.ejca.2015.02.003","journal-title":"Eur J Cancer"},{"key":"1252_CR38","first-page":"130","volume":"12","author":"K Dasgupta","year":"2006","unstructured":"Dasgupta K, Di Cesar D, Ghosn J, Rajan R, Mahmud S, Rahme E (2006) Association between nonsteroidal anti-inflammatory drugs and prostate cancer occurrence. Cancer J 12:130\u2013135","journal-title":"Cancer J"},{"key":"1252_CR39","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/bjc.2012.227","volume":"107","author":"FM Shebl","year":"2012","unstructured":"Shebl FM, Sakoda LC, Black A, Koshiol J, Andriole GL, Grubb R, Church TR, Chia D, Zhou C, Chu LW, Huang WY, Peters U, Kirsh VA, Chatterjee N, Leitzmann MF, Hayes RB, Hsing AW (2012) Aspirin but not ibuprofen use is associated with reduced risk of prostate cancer: a PLCO study. Br J Cancer 107:207\u2013214. https:\/\/doi.org\/10.1038\/bjc.2012.227","journal-title":"Br J Cancer"},{"key":"1252_CR40","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1158\/1078-0432.ccr-14-2235","volume":"21","author":"AC Vidal","year":"2015","unstructured":"Vidal AC, Howard LE, Moreira DM, Castro-Santamaria R, Andriole GL, Freedland SJ (2015) Aspirin, NSAIDs, and risk of prostate cancer: results from the REDUCE study. Clin Cancer Res 21:756\u2013762. https:\/\/doi.org\/10.1158\/1078-0432.ccr-14-2235","journal-title":"Clin Cancer Res"},{"key":"1252_CR41","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1002\/cam4.1186","volume":"6","author":"S Doat","year":"2017","unstructured":"Doat S, C\u00e9n\u00e9e S, Tr\u00e9tarre B, Rebillard X, Lamy PJ, Bringer JP, Iborra F, Murez T, Sanchez M, Menegaux F (2017) Nonsteroidal anti-inflammatory drugs (NSAIDs) and prostate cancer risk: results from the EPICAP study. Cancer Med 6:2461\u20132470. https:\/\/doi.org\/10.1002\/cam4.1186","journal-title":"Cancer Med"},{"key":"1252_CR42","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41391-017-0021-x","volume":"21","author":"Y Ma","year":"2018","unstructured":"Ma Y, Brusselaers N (2018) Maintenance use of aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs) and prostate cancer risk. Prostate Cancer Prostatic Dis 21:147\u2013152. https:\/\/doi.org\/10.1038\/s41391-017-0021-x","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1252_CR43","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.ejca.2012.09.030","volume":"49","author":"T Veitonm\u00e4ki","year":"2013","unstructured":"Veitonm\u00e4ki T, Tammela TL, Auvinen A, Murtola TJ (2013) Use of aspirin, but not other non-steroidal anti-inflammatory drugs is associated with decreased prostate cancer risk at the population level. Eur J Cancer 49:938\u2013945. https:\/\/doi.org\/10.1016\/j.ejca.2012.09.030","journal-title":"Eur J Cancer"},{"key":"1252_CR44","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1038\/bjc.2014.381","volume":"111","author":"T Veitonm\u00e4ki","year":"2014","unstructured":"Veitonm\u00e4ki T, Murtola TJ, M\u00e4\u00e4tt\u00e4nen L, Taari K, Stenman UH, Tammela TL, Auvinen A (2014) Prostate cancer risk and nonsteroidal antiinflammatory drug use in the Finnish prostate cancer screening trial. Br J Cancer 111:1421\u20131431. https:\/\/doi.org\/10.1038\/bjc.2014.381","journal-title":"Br J Cancer"},{"key":"1252_CR45","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrurol.2017.167","volume":"15","author":"KS Sfanos","year":"2018","unstructured":"Sfanos KS, Yegnasubramanian S, Nelson WG, De Marzo AM (2018) The inflammatory microenvironment and microbiome in prostate cancer development. Nat Rev Urol 15:11\u201324. https:\/\/doi.org\/10.1038\/nrurol.2017.167","journal-title":"Nat Rev Urol"},{"key":"1252_CR46","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s13075-015-0728-9","volume":"17","author":"TA Simon","year":"2015","unstructured":"Simon TA, Thompson A, Gandhi KK, Hochberg MC, Suissa S (2015) Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. Arthritis Res Ther 17:212. https:\/\/doi.org\/10.1186\/s13075-015-0728-9","journal-title":"Arthritis Res Ther"},{"key":"1252_CR47","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1053\/j.semnuclmed.2016.07.002","volume":"46","author":"M Nguyen-Nielsen","year":"2016","unstructured":"Nguyen-Nielsen M, Borre M (2016) Diagnostic and therapeutic strategies for prostate cancer. Semin Nucl Med 46:484\u2013490. https:\/\/doi.org\/10.1053\/j.semnuclmed.2016.07.002","journal-title":"Semin Nucl Med"},{"key":"1252_CR48","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2147\/CLEP.S59156","volume":"6","author":"M Schmidt","year":"2014","unstructured":"Schmidt M, Hallas J, Friis S (2014) Potential of prescription registries to capture individual-level use of aspirin and other nonsteroidal anti-inflammatory drugs in Denmark: trends in utilization 1999\u20132012. Clin Epidemiol 6:155\u2013168. https:\/\/doi.org\/10.2147\/CLEP.S59156","journal-title":"Clin Epidemiol"},{"key":"1252_CR49","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1111\/add.13341","volume":"111","author":"A Kalinowski","year":"2016","unstructured":"Kalinowski A, Humphreys K (2016) Governmental standard drink definitions and low-risk alcohol consumption guidelines in 37 countries. Addiction 111:1293\u20131298. https:\/\/doi.org\/10.1111\/add.13341","journal-title":"Addiction"}],"container-title":["Cancer Causes &amp; Control"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10552-019-01252-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10552-019-01252-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10552-019-01252-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T02:28:06Z","timestamp":1607480886000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10552-019-01252-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,10]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["1252"],"URL":"https:\/\/doi.org\/10.1007\/s10552-019-01252-5","relation":{},"ISSN":["0957-5243","1573-7225"],"issn-type":[{"type":"print","value":"0957-5243"},{"type":"electronic","value":"1573-7225"}],"subject":[],"published":{"date-parts":[[2019,12,10]]},"assertion":[{"value":"28 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Professor S\u00f8rensen does not report receiving fees, honoraria, grants, or consultancies. Department of Clinical Epidemiology is, however, involved in studies with funding from various companies as research grants to (and administered by) Aarhus University. Authors not named here have disclosed no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The DCH Study was approved by relevant Scientific Committees and the Danish Data Protection Agency.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all participants to retrieve information from nationwide registries []. Approval for medical record review was granted by the Danish National Committee on Health Research Ethics.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}